AZD1390: ATM Kinase Inhibitor Workflow

DNA damage response experiments often fail when radiation exposure, inhibitor handling, and mechanistic readouts are treated as separate variables. AZD1390 offers a focused way to interrogate ATM kinase activity while preserving a practical experimental design for cell-cycle, apoptosis, micronucleus, and replication-stress studies. The compound is especially useful when the research question involves whether ATM signaling helps tumor cells tolerate DNA double-strand breaks generated by ionizing radiation.

For reagent specifications, the AZD1390 product information from APExBIO reports a cellular IC50 of 0.78 nM. It also describes effective ATM inhibition at 3 nM in glioblastoma LN18 cells and radiation-associated activity at 10 nM in NCI-H2228 lung cancer cells. These values are useful anchors rather than universal doses: cell density, genotype, radiation schedule, exposure duration, and assay endpoint can all shift the concentration-response relationship.

Setup and Principle: What AZD1390 Adds to DNA Damage Experiments

ATM is a serine/threonine kinase in the phosphatidylinositol 3-kinase-related kinase family. Following DNA double-strand breaks, ATM signaling coordinates repair-associated responses and cell-cycle checkpoint regulation, limiting premature progression into mitosis. In a radiation experiment, this creates a testable model: radiation supplies the damage, while AZD1390 suppresses an ATM-dependent survival and checkpoint branch.

Accordingly, AZD1390 can function as an ATM kinase inhibitor and as a pharmacological DNA double-strand break repair inhibitor in a carefully controlled experimental context. The most informative design compares vehicle, AZD1390 alone, radiation alone, and the combination. A combination-specific increase in micronuclei, prolonged arrest, or apoptosis is more persuasive than reduced viability alone because it links the phenotype to genome instability and damage processing.

The compound is a solid with a molecular weight of 477.57. The product information reports water insolubility, DMSO solubility of at least 19.6 mg/mL, and ethanol solubility of at least 3.04 mg/mL with gentle warming and ultrasonic treatment. These properties make stock preparation a central part of assay reproducibility. Freshly prepared, well-mixed stocks and a matched solvent control are usually more important than simply increasing the inhibitor concentration.

Key Innovation from the Reference Study

The Nucleic Acids Research reference study identifies a direct interaction between the REV1 C-terminal domain and the G-quadruplex helicase DHX36. The work places REV1 at the center of a two-tier mechanism: DHX36-associated G-quadruplex resolution supports fork progression, while REV1 helps restrain PrimPol-driven synthesis and suppress persistent single-stranded DNA gaps. Loss of REV1 altered fork elongation, increased nuclear G-quadruplex signal, amplified ATM/ATR signaling, and sensitized cells to G-quadruplex stabilization.

This finding changes how an ATM inhibitor can be used in replication-stress assays. Rather than interpreting increased ATM signaling as a generic marker of toxicity, investigators can ask whether ATM activity is compensating for a defined fork obstacle. A useful assay choice is to measure a replication or G-quadruplex phenotype first, then add AZD1390 to determine whether the ATM response is protective, neutral, or damaging in that context.

• Use REV1 or DHX36 perturbation, where experimentally appropriate, to define the replication-stress background.
• Measure nuclear G-quadruplex signal, ssDNA-gap behavior, fork progression, and ATM/ATR pathway activation as separate endpoints rather than combining them into one viability result.
• Include AZD1390 alone and in combination with radiation or a G-quadruplex-stabilizing condition to distinguish damage induction from damage-response inhibition.

AZD1390 does not by itself demonstrate a direct REV1–DHX36 interaction or G-quadruplex unwinding. Its value here is as a mechanistic probe for the ATM component of a stress response described by the reference study.

Why this cross-domain matters, maturity, and limitations

The connection between G-quadruplex tolerance and ATM inhibition is biologically plausible but still an emerging bridge. The reference study directly supports links among REV1 loss, replication-fork defects, G-quadruplex accumulation, and ATM/ATR signaling. Separately, the AZD1390 dossier supports ATM inhibition and radiation sensitization in glioma and lung cancer models. The combination of these evidence streams supports a hypothesis-driven workflow, not a claim that AZD1390 has already been validated as a REV1–DHX36 therapy. Matched genetic controls, orthogonal damage markers, and radiation-only controls are therefore essential.

Protocol Parameters

• Stock preparation: Prepare a 10 mM AZD1390 stock in DMSO by dissolving 4.78 mg in 1 mL, using gentle warming at 20–25°C and ultrasonic treatment for approximately 5 minutes if needed. Aliquot and store at −20°C.
• Cellular concentration design: Start a 0.3, 1, 3, 10, and 30 nM concentration series. Use 3 nM as a literature-informed LN18 anchor and 10 nM as a literature-informed NCI-H2228 radiation-combination anchor, while treating the remaining points as workflow recommendations.
• Exposure timing: Add AZD1390 1 hour before irradiation and maintain the treatment through a 24-hour recovery period for an initial comparison. Optimize the pretreatment window at 0.5, 1, and 2 hours if the combination effect is weak.
• Radiation matrix: Compare 0, 2, 4, and 6 Gy in a single experiment, then collect material at 2, 6, 24, and 48 hours. These radiation doses and time points are practical design suggestions and should be adapted to the instrument and cell line.
• Vehicle control: Keep final DMSO at or below 0.1% v/v across all wells, including controls, and use a minimum working volume of 100 µL per 96-well assay well to reduce evaporation-driven concentration changes.
• In vivo translation: The product information describes dose-dependent activity in an orthotopic lung-brain tumor rat model, with stronger efficacy reported at 20 mg/kg orally when combined with ionizing radiation. Reproduction requires matching the approved animal protocol, formulation, dosing interval, and radiation schedule rather than inferring them from the dose alone.

Step-by-Step Workflow Enhancements

1. Qualify the culture: Confirm mycoplasma-free status, record passage number, and seed cells so that vehicle wells reach comparable confluence at irradiation. Overconfluent cultures can blunt both radiation response and cell-cycle resolution.
2. Run a concentration screen: Establish AZD1390-alone viability and cell-cycle profiles before adding radiation. This identifies concentrations that inhibit ATM without producing excessive baseline toxicity.
3. Apply the four-condition design: Use vehicle, AZD1390, radiation, and combination groups. Include biological replicates and randomize plate position when using high-content imaging.
4. Separate early and late readouts: Assess ATM pathway changes and checkpoint markers at early time points, then evaluate micronuclei, apoptosis, clonogenic survival, or viability later. A single endpoint can miss transient checkpoint activation followed by delayed cell death.
5. Analyze interaction rather than only effect size: Compare observed combination responses with an additive reference model such as Bliss or Loewe. Report the model, replicate number, and confidence interval so that radiosensitization is not confused with independent toxicity.

For a broader assay-oriented discussion, AZD1390: Reliable ATM Kinase Inhibitor for Radiosensitization complements this workflow by emphasizing controls and reproducibility. The REV1–DHX36 Coordination of G-Quadruplex Tolerance article extends the design into replication-fork and G-quadruplex biology; it should be viewed as a mechanistic extension, not as direct validation of AZD1390 in that pathway.

Advanced Applications and Comparative Advantages

AZD1390 is particularly suited to experiments asking whether ATM-mediated checkpoint activity protects damaged tumor cells. In LN18 glioma cells, the reported 3 nM activity provides a low-nanomolar starting point for glioblastoma radiosensitization studies. The dossier also describes enhanced radiosensitization in p53 mutant glioma cells, making p53 genotype a useful stratification variable rather than an afterthought.

In NCI-H2228 lung cancer cells, the reported 10 nM radiation combination is associated with G2 arrest, micronuclei formation, and apoptosis. These distinct outcomes support a layered workflow: quantify cell-cycle distribution, image micronuclei, and confirm apoptosis with an independent assay. This is more informative than relying on a single metabolic viability signal.

The main comparative advantage of a potent, selective ATM inhibitor is experimental resolution. Low-nanomolar dosing can create a narrower perturbation window than broad DNA-damaging treatments, allowing researchers to test ATM signaling without intentionally introducing a second large chemical insult. Selectivity should still be verified in the chosen system with pathway-level controls; potency alone does not prove that every downstream phenotype is ATM-specific.

Troubleshooting and Optimization Tips

Precipitation or uneven dosing

Because AZD1390 is insoluble in water, adding a concentrated DMSO stock directly to aqueous medium can cause local precipitation. Pre-dilute the stock into a small volume of warmed, serum-compatible medium, mix thoroughly, and add it rapidly to the culture. Inspect wells microscopically after dosing. If visible particles remain, reduce the intermediate dilution step, confirm stock clarity, and avoid storing diluted working solutions for extended periods.

Weak radiosensitization

First verify the radiation calibration, delivered dose, cell density, and timing between dosing and irradiation. Confirm that the selected concentration inhibits an ATM-responsive readout without causing substantial AZD1390-alone toxicity. Compare a 0.5-, 1-, and 2-hour pretreatment series, and analyze p53-defined cell backgrounds separately. A weak viability effect does not exclude pathway modulation if cell-cycle or DNA damage endpoints change.

High background apoptosis

High baseline death can result from excessive solvent, poor culture health, overconfluence, or an overly long exposure window. Use a fresh vehicle control, reduce the DMSO fraction, shorten the initial exposure, and repeat the concentration series at lower doses. Maintain identical medium changes across radiation and non-radiation groups.

Inconsistent cell-cycle or micronucleus data

Standardize harvest timing and use the same fixation, imaging exposure, and segmentation thresholds across plates. Micronuclei should be scored with nuclear morphology criteria established before unblinding. If G2 arrest is transient, a single 24-hour collection may be insufficient; add early and late sampling points. Pair imaging with flow cytometry or a biochemical checkpoint readout.

Stock degradation or loss of potency

The product information recommends storage at −20°C and states that long-term storage of solutions is not recommended. Prepare small aliquots, limit freeze–thaw cycles, label preparation dates, and discard solutions showing precipitation or unexplained assay drift. Keep the solid and stock-handling records separate from biological batch records so reagent problems can be distinguished from cell-line variability.

Future Outlook

AZD1390 can help move ATM research from descriptive radiation sensitivity toward mechanism-resolved cancer research. The strongest next step is to combine its radiation workflow with the reference study’s REV1–DHX36 framework: define the replication obstacle, measure G-quadruplex and ssDNA-gap phenotypes, and then test how ATM inhibition changes the outcome. This approach may clarify why some glioma or lung cancer backgrounds show strong radiosensitization while others primarily exhibit checkpoint changes.

Future studies should preserve the evidence boundaries. The current data support AZD1390 as a selective ATM kinase inhibitor with utility in radiation-response models, while the 2026 reference study supports a distinct REV1–DHX36 mechanism for G-quadruplex tolerance. Carefully integrated controls can test the relationship between these findings without treating a promising mechanistic connection as an established therapeutic combination.